Electro-Optical Sciences, Inc. announced additional data on MelaFind phase III pivotal study at a symposium at the American Academy of Dermatology's (AAD) 67th Annual Meeting held in San Francisco March 2009. MelaFind is a non-invasive, point-of-care instrument to assist in the early detection of melanoma. The company plans to submit Pre-Market Approval (PMA) application, which it expects to file with the US Food and Drug Administration (FDA) shortly. This largest prospective pivotal study conducted in melanoma detection, included 1,831 pigmented skin lesions from 1,383 patients. As previously announced, MelaFind detected 112 of 114 (98% sensitivity; lower confidence bound of 95%) melanomas that were eligible and evaluable for primary sensitivity endpoint analysis, and 125 of 127 (98% sensitivity; lower confidence bound greater than 95%) melanomas overall. MelaFind's specificity, the ability to accurately rule out disease, was significantly superior (9.5%) to that of the study dermatologists (3.7%), who are skin cancer experts (p-value less than 0.02). In order to generate a comparison with dermatologists' ability to accurately detect melanoma, EOS conducted a parallel pilot readers' study with a different group of 39 dermatologists. Using images and clinical histories of 23 randomly-selected melanomas from the pivotal study, this group of dermatologists, on average, would have decided to biopsy only approximately 18 (80%) of the melanomas, whereas the MelaFind result would have led to a biopsy of 22 of the melanomas (biopsy sensitivity of 96%).